Nureca Ltd. AI Stock Analysis
Want to see IN:NURECA full AI Analyst Report?
Nureca Ltd. (NURECA) AI Stock Analysis
Nureca Ltd.
(NSE:NURECA)
Nureca's score is primarily driven by robust technical momentum and a highly conservative, debt-free balance sheet. While the recent return to top-line growth and positive cash flow are encouraging fundamental strengths, the stock's stretched valuation (88.5x P/E) and remarkably thin profit margins present notable headwinds that limit the overall rating.
Nureca Ltd. (NURECA) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 3.02B
- Dividend Yield
- ―
- Average Volume (3M)
- 861
- Price to Earnings (P/E)
- 63.8
- Beta (1Y)
- 0.79
- Revenue Growth
- 33.66%
- EPS Growth
- 17.10%
- Country
- India
- Employees
- 154
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Nureca Ltd. Business Overview & Revenue Model
Company Description
Operating in India, Nureca Limited is a business-to-consumer (B2C) firm specializing in home healthcare and general wellness solutions. Their extensive product portfolio addresses various health needs, encompassing items for managing chronic conditio...
Nureca Ltd. Financial Statement Overview
Summary
Nureca features a fortress balance sheet with a negligible debt-to-equity ratio of 0.01x. Recent recoveries in revenue growth and net income are positive, though compressed profit margins (1.4% net margin) and a sluggish return on equity constrain the score.
Income Statement
60NeutralBalance Sheet
85Very PositiveCash Flow
55Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.74B | 1.47B | 1.10B | 919.28M | 1.11B | 2.56B |
| Gross Profit | 444.82M | 352.34M | 231.33M | 311.42M | 355.94M | 1.23B |
| EBITDA | 111.18M | 85.19M | 48.95M | 2.41M | -79.04M | 632.04M |
| Net Income | 47.60M | 20.82M | 8.46M | -17.94M | -82.50M | 449.60M |
Balance Sheet | ||||||
| Total Assets | 2.31B | 1.96B | 2.10B | 2.05B | 2.07B | 2.19B |
| Cash, Cash Equivalents and Short-Term Investments | 735.52M | 424.31M | 736.29M | 1.44B | 1.02B | 927.10M |
| Total Debt | 66.01M | 22.59M | 49.66M | 25.16M | 33.27M | 44.05M |
| Total Liabilities | 433.97M | 153.96M | 156.91M | 120.54M | 116.97M | 159.32M |
| Stockholders Equity | 1.88B | 1.81B | 1.94B | 1.93B | 1.95B | 2.03B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 17.45M | -234.06M | -37.98M | 98.31M | -46.00M |
| Operating Cash Flow | 0 | 85.74M | -190.83M | -27.12M | 102.27M | 13.99M |
| Investing Cash Flow | 0 | 81.20M | 84.39M | 175.76M | -164.56M | -30.89M |
| Financing Cash Flow | 0 | -184.66M | -1.69M | -13.03M | -15.07M | -73.02M |
Nureca Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NURECA, the sentiment is Negative. The current price of 295.90 is below the 20-day moving average (MA) of 307.00, below the 50-day MA of 324.50, and above the 200-day MA of 286.62, indicating a neutral trend. The MACD of -7.60 indicates Positive momentum. The RSI at 37.01 is Neutral, neither overbought nor oversold. The STOCH value of 28.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NURECA.
Nureca Ltd. Peers Comparison
Overall Rating
IN:BLUEJET71Outperform
IN:NURECA68Neutral
IN:PGHL64Neutral
IN:AMRUTANJAN62Neutral
IN:ZOTA45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | INR 96.53B | 32.40 | ― | 0.23% | -7.05% | -21.25% | |
| 68Neutral | INR 2.82B | 63.79 | ― | ― | 33.66% | 17.10% | |
| 64Neutral | INR 90.83B | 24.06 | ― | 3.84% | 13.04% | 4.60% | |
| 62Neutral | INR 14.87B | 26.05 | ― | 0.95% | 10.68% | -1.04% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | INR 39.87B | -39.19 | ― | 0.08% | 68.95% | -55.82% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:NURECA | Nureca Ltd. | 295.90 | 39.65 | 15.47% | |
| IN:AMRUTANJAN | Amrutanjan Health Care Limited | 515.90 | -173.88 | -25.21% | |
| IN:BLUEJET | Blue Jet Healthcare Limited | 517.90 | -36.19 | -6.53% | |
| IN:PGHL | Procter & Gamble Health Ltd. | 5503.25 | -116.14 | -2.07% | |
| IN:SANOFICONR | Sanofi Consumer Healthcare India Limited | 3528.50 | -1145.36 | -24.51% | |
| IN:ZOTA | Zota Health Care Ltd. | 1314.50 | -369.13 | -21.92% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 29, 2026
